Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Isofol Medical: AGENT phase III trial fails - DNB

Isofol Medical

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Isofol Medical announced that the phase III trial AGENT had failed to reach its primary and most important secondary endpoints. This is a huge disappointment and reduces the company’s valuation significantly (as arfolitixorin – the drug evaluated in the AGENT trial – was its only asset in clinical development). We have cut our fair value to SEK0–3 (14–26).
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.